3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The role of uPA in tissue remodeling and cell migration is already well established. In addition, uPA was reported to stabilize p53, a key cell cycle control, DNA repair and apoptosis initiation protein. We aimed to determine the role of uPA-uPAR signaling towards cell survival or apoptosis in human adult cardiac myocytes (HACM). HACM were stimulated with uPA and DNA damage was inflicted by incubating cells with 200 µM H 2O 2. To analyze for apoptotic cells we applied TUNEL staining. Oxidative damage foci were analyzed by staining for 8-oxoguanine base pairs. In vivo qPCR analysis from RNA extracted from failing human hearts demonstrated a close relation of uPA with apoptosis and the p53 pathway. Furthermore, we observed a close correlation of uPA and p53 protein in homogenized tissue lysates. In vitro studies revealed that uPA preincubation protected HACM from oxidative damage induced cell death and reduced oxidative damage foci. uPA protection is independent of its catalytic activity, as the amino terminal fragment of uPA showed similar protection. A key enzyme for repairing oxidative DNA damage is the p53 target hOGG1. We found a significant increase of hOGG1 after pretreatment of HACM with uPA. Knockdown of hOGG1 completely abrogated the protective effect of uPA. We conclude that uPA might have a tissue protective role in human hearts besides its role in tissue remodeling. Tissue protection is mediated by the DNA repair protein hOGG1. This might be beneficial during tissue remodeling and thus could be a target for therapeutic approaches in the diseased heart.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          The first 30 years of p53: growing ever more complex.

          Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of cell signalling by uPAR.

            Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways. Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling. Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              p53 Family and Cellular Stress Responses in Cancer

              p53 is an important tumor suppressor gene, which is stimulated by cellular stress like ionizing radiation, hypoxia, carcinogens, and oxidative stress. Upon activation, p53 leads to cell-cycle arrest and promotes DNA repair or induces apoptosis via several pathways. p63 and p73 are structural homologs of p53 that can act similarly to the protein and also hold functions distinct from p53. Today more than 40 different isoforms of the p53 family members are known. They result from transcription via different promoters and alternative splicing. Some isoforms have carcinogenic properties and mediate resistance to chemotherapy. Therefore, expression patterns of the p53 family genes can offer prognostic information in several malignant tumors. Furthermore, the p53 family constitutes a potential target for cancer therapy. Small molecules (e.g., Nutlins, RITA, PRIMA-1, and MIRA-1 among others) have been objects of intense research interest in recent years. They restore pro-apoptotic wild-type p53 function and were shown to break chemotherapeutic resistance. Due to p53 family interactions small molecules also influence p63 and p73 activity. Thus, the members of the p53 family are key players in the cellular stress response in cancer and are expected to grow in importance as therapeutic targets.
                Bookmark

                Author and article information

                Contributors
                +43 1 40400 73515 , philipp.hohensinner@meduniwien.ac.at
                Journal
                Apoptosis
                Apoptosis
                Apoptosis
                Springer US (New York )
                1360-8185
                1573-675X
                22 June 2017
                22 June 2017
                2017
                : 22
                : 8
                : 1048-1055
                Affiliations
                [1 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Department of Internal Medicine II, Cardiology, , Medical University of Vienna, ; Währingergürtel 18-20, 1090 Vienna, Austria
                [2 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Department of Surgery, , Medical University of Vienna, ; Vienna, Austria
                [3 ]ISNI 0000 0004 0524 3028, GRID grid.417109.a, 3rd Medical Department, , Wilhelminenhospital, ; Vienna, Austria
                [4 ]GRID grid.454395.a, , Ludwig Boltzmann Cluster for Cardiovascular Research, ; Vienna, Austria
                Article
                1388
                10.1007/s10495-017-1388-9
                5486847
                28643198
                cea6a908-ab95-4cbb-9b2a-8dbff7c1331d
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                Funding
                Funded by: Association for the Promotion of Research on Arteriosclerosis, Thrombosis and Vascular Biology
                Funded by: Ludwig Boltzmann Cluster for Cardiovascular Research
                Categories
                Short Communication
                Custom metadata
                © Springer Science+Business Media, LLC 2017

                Molecular biology
                urokinase plasminogen activator,oxidative dna damage,hogg1,p53 pathway
                Molecular biology
                urokinase plasminogen activator, oxidative dna damage, hogg1, p53 pathway

                Comments

                Comment on this article